MARCH 30 2021 Sean Whooley Glytec launches new insulin management system Glytec announced today that it introduced the latest version of its eGlycemic Management System (eGMS) for managing insulin. Waltham, Mass.-based Glytec’s eGMS is centered around the FDA-cleared Glucommander algorithm, which leverages real-time and historical data to recommend insulin dosing by learning each patient’s insulin sensitivity and anticipating future needs, …
MARCH 31 2021 Amy Reyes Diabetic Ketoacidosis With COVID-19 Fatal for Elderly and Obese Diabetes Patients Patients with diabetic ketoacidosis and a COVID-19 diagnosis died at increasingly higher rates than diabetic ketoacidosis patients without COVID-19, shows an analysis recently published in JAMA Network Open. Published online March 10 as a research letter, physicians led by Francisco J. Pasquel, MD, MPH, …
MARCH 23 2021 Medically reviewed by Michelle L. Griffith, MD — Written by Ashley Zlatopolsky 7 Things Certified Diabetes Educators Want You to Know About Managing Diabetes Taking care of yourself is an important part of managing type 2 diabetes. It often involves making changes to your diet and lifestyle, developing a workout plan, taking your medications, and monitoring your blood sugar level …
MARCH 10 2021 Kristen Monaco COVID-19 and Diabetic Ketoacidosis a Deadly Mix? — Nearly half of COVID-19-positive DKA patients over 65 died in the hospital COVID-19 appeared to increase risk of mortality in people hospitalized with diabetic ketoacidosis (DKA), researchers reported. In a comparison of hospitalized DKA patients from February to September 2020, 30% of those who also had COVID-19 …
MARCH 10 2021 Miriam Tucker COVID-19 Complicates Diabetic Ketoacidosis in Hospital The clinical course and prognosis of individuals hospitalized with diabetic ketoacidosis (DKA) are considerably worse among those who have COVID-19, new data show. In-hospital death was sixfold greater among patients with DKA who had COVID-19 compared with those who did not, and acute kidney injury was three times more common. “These findings …
DECEMBER 2020 Ling Cui, Pamela R. Schroeder and Paul A. Sack Inpatient and Outpatient Technologies to Assist in the Management of Insulin Dosing Simplified systems were initially developed using this construct to help adjust insulin infusions, but more complex software has since been developed to account for a variety of clinical inpatient scenarios. FDA-approved inpatient electronic glycemic management systems include Glucommander (Glytec), EndoTool …
FEBRUARY 2021 Dawn Antoline-Wang Glycemia in Early COVID-19 Hospitalization Linked to Mortality Improved glycemia within the first two or three days of hospitalization is a better predictor of outcomes in COVID-19 patients than glycemia at the time of non-intensive-care-unit (ICU) hospital admission, according to new findings. Glycemia soon after direct ICU admission was not predictive of outcomes in these patients, Dr. …
AdventHealth Waterman and Sentara Virginia Beach General Hospital showcased reductions in hypoglycemia and glycemic practice variation utilizing Glytec’s comprehensive systems approach to glucose management.
In partnership with clinical leaders from AdventHealth Waterman and Sentara Virginia Beach General Hospital, Glytec presented two storyboards at the IHI National Forum revealing significant quality and safety improvements for hospitalized patients receiving insulin therapy. On average, this population represents as many as one of every three patients admitted to a general ward and one of every two patients admitted to an intensive care unit. Both hospitals credit their collaboration with Glytec, including utilization of the company’s FDA-cleared decision support platform, eGlycemic Management System® (eGMS®), as well as the company’s highly-tailored quality improvement services.
Georgia’s largest health system is heightening the safety and efficacy of insulin therapy across its network of hospitals.
Known nationally for innovative care models, WellStar Health System, in partnership with Glytec, is taking proactive measures to optimize glycemic management for hospitalized patients. The not-for-profit health system is expanding use of Glytec’s patented and FDA-cleared eGlycemic Management System® (eGMS®) beyond its two largest facilities, WellStar Kennestone Hospital and WellStar Atlanta Medical Center, to an additional eight facilities in the Greater Atlanta and surrounding area.
Results of a study by Drs. Guillermo Umpierrez and Jordan Messler observed markedly lower rates of hypoglycemia and hyperglycemia among critical care patients managed with Glytec’s eGlycemic Management System® versus usual care.
Delivering the highest quality care in accordance with best practice is a fundamental tenet of diabetes and glycemic management at Grady Hospital of Atlanta, Georgia, which is why in 2016, the academic medical center chose to standardize its approach and elevate both safety and efficacy by implementing Glytec’s eGlycemic Management System® (eGMS®) in its intensive care and step-down units. A retrospective analysis conducted by Drs. Guillermo Umpierrez and Jordan Messler, and presented at the American Diabetes Association 79th Scientific Sessions, observed that outcomes of patients managed with eGMS® were consistently superior to those managed with a standard protocol. Outcomes measured over a two-year period (December 2016 to December 2018) included incidence of hypoglycemia, incidence of hyperglycemia, target glucose attainment, and reduction in admission-to-discharge blood glucose.
The Wyoming, Michigan-based healthcare organization will partner with Glytec to provide patients an integrated model of technology-enabled glycemic management.
Known for high-quality, personalized care and award-winning services, Metro Health – University of Michigan Health is taking inpatient diabetes management to the next level. With a decades-long focus on ensuring glucose control is a top priority, the healthcare organization has selected Glytec’s eGlycemic Management System® (eGMS®) to advance the standardization of best practice. The software-as-a-medical-device eGMS® platform is both patented and FDA cleared.
Nearly three dozen AHS acute care facilities are live with Glytec’s software for intravenous insulin optimization.
Adventist Health System (AHS), one of the largest faith-based health systems in the U.S., has successfully deployed the eGlycemic Management System® from Glytec. As a result, 33 AHS acute care facilities across seven states are now utilizing Glytec’s solution for intravenous insulin optimization.
Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.
Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.
Glytec’s eGlycemic Management System® will ensure clinicians have ready access to evidence-based decision support for personalized insulin therapy management.
Fostering a culture of patient safety is integral to the care Chesapeake Regional Healthcare delivers, and a new partnership with Glytec will enable best practices in glycemic management across all inpatient service lines. Glytec’s eGlycemic Management System® will support the optimization of intravenous and subcutaneous insulin therapy during hospitalization, and will provide evidence-based guidance on transitions in insulin therapy from hospital to home.
Diabetes educators learned how Glytec’s software and other data-driven technologies help overcome key challenges of insulin management.
A presentation on diabetes decision support solutions at this year’s American Association of Diabetes Educators (AADE) conference showcased how use of Glytec’s therapy management software in conjunction with connected device systems is breaking down barriers to effective and timely insulin management and, as a result, reducing the risks and costs of diabetes for providers, payers and patients alike.
One study presented at the International Hospital Diabetes Meeting observed first-year cost savings of nearly $7.5 million stemming from adoption of best practice for insulin therapy.
A series of studies and presentations included in the 6th International Hospital Diabetes Meeting highlighted the high cost of poor glucose management, and in particular, severe hypoglycemia (< 40 mg/dL) in the acute care setting. With thirty to forty percent of ALL hospitalized patients requiring insulin therapy, not just those with diabetes, the common problem of insulin mismanagement has significant impact on care quality, patient safety and patient experience, as well as cost and value.
Drs. Umpierrez and Cardona publish economic and clinical results of the GLUCO-CABG trial, leveraging Glytec’s Glucommander™ for personalized insulin dosing.
A study from Emory University published in the April 2017 issue of Journal of Diabetes and Its Complications (Cardona, et al. 2017) observes a near-20% reduction in perioperative complications, a 1.2-day reduction in ICU stay and a $3,654 reduction in per-patient hospitalization costs for coronary artery bypass graft (CABG) surgery. The reported outcomes, which included no severe hypoglycemia less than 40 mg/dL, were derived from an intensive glycemic control protocol supported by Glytec’s Glucommander™ for personalized insulin dosing.
Glytec’s system for personalized diabetes therapy management translates to better quality of care at Atlanta’s Grady Health System.
In its quest to ensure high quality care for critically ill patients, Atlanta’s Grady Health System has implemented the evidence-based Glytec eGlycemic Management System® (eGMS®), a personalized diabetes therapy management solution.
The findings come as CMS targets cardiac procedures in both its hospital readmission reduction program and in a bundled payment model set to take effect July 1, 2017.
Glytec, which has FDA clearance for a cloud-based system to manage insulin dosing, selected MSHA as a research site for its electronic glucose management system, or eGMS. According to the studies Parsons and Mumpower presented in November at the Diabetes Technology Meeting showcase, eGMS produced sharp drops in readmission rates in 3 areas of cardiac care.
Two studies presented at the 16th Annual Diabetes Technology Meeting showcase readmission reductions as high as 68% with Glytec’s solution.
Two new studies presented at last week’s Diabetes Technology Meeting further validate the ability of Glytec’s eGlycemic Management System® (eGMS®) to achieve dramatic readmission reductions for patient populations at the center of new at-risk and value-based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).